

Hilal A Lashuel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1284628/publications.pdf>

Version: 2024-02-01

128
papers

14,495
citations

28190

55
h-index

20900

115
g-index

158
all docs

158
docs citations

158
times ranked

13605
citing authors

#	ARTICLE	IF	CITATIONS
1	The many faces of $\hat{\pm}$ -synuclein: from structure and toxicity to therapeutic target. <i>Nature Reviews Neuroscience</i> , 2013, 14, 38-48.	4.9	1,322
2	Amyloid pores from pathogenic mutations. <i>Nature</i> , 2002, 418, 291-291.	13.7	1,182
3	$\hat{\pm}$ -Synuclein, Especially the Parkinson's Disease-associated Mutants, Forms Pore-like Annular and Tubular Protofibrils. <i>Journal of Molecular Biology</i> , 2002, 322, 1089-1102.	2.0	772
4	A century-old debate on protein aggregation and neurodegeneration enters the clinic. <i>Nature</i> , 2006, 443, 774-779.	13.7	621
5	Amyloidogenic Proteinâ€™Membrane Interactions: Mechanistic Insight from Model Systems. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 5628-5654.	7.2	529
6	$\hat{\pm}$ -Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer. <i>Journal of Biological Chemistry</i> , 2012, 287, 15345-15364.	1.6	466
7	The process of Lewy body formation, rather than simply $\hat{\pm}$ -synuclein fibrillization, is one of the major drivers of neurodegeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4971-4982.	3.3	422
8	Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?. <i>Quarterly Reviews of Biophysics</i> , 2006, 39, 167-201.	2.4	365
9	Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of $\hat{\pm}$ -Synuclein. <i>Journal of Biological Chemistry</i> , 2008, 283, 16895-16905.	1.6	302
10	Protofilaments, Filaments, Ribbons, and Fibrils from Peptidomimetic Self-Assembly:â€™ Implications for Amyloid Fibril Formation and Materials Science. <i>Journal of the American Chemical Society</i> , 2000, 122, 5262-5277.	6.6	286
11	Role of post-translational modifications in modulating the structure, function and toxicity of $\hat{\pm}$ -synuclein. <i>Progress in Brain Research</i> , 2010, 183, 115-145.	0.9	283
12	Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits $\hat{\pm}$ -Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions. <i>Journal of Neuroscience</i> , 2010, 30, 3184-3198.	1.7	271
13	Amyloid- $\hat{\pm}^2$ Aggregates Cause Alterations of Astrocytic Metabolic Phenotype: Impact on Neuronal Viability. <i>Journal of Neuroscience</i> , 2010, 30, 3326-3338.	1.7	252
14	Highly Efficient and Chemoselective Peptide Ubiquitylation. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 8090-8094.	7.2	241
15	The Ratio of Monomeric to Aggregated Forms of $\hat{\pm}^{240}$ and $\hat{\pm}^{242}$ Is an Important Determinant of Amyloid- $\hat{\pm}^2$ Aggregation, Fibrillogenesis, and Toxicity. <i>Journal of Biological Chemistry</i> , 2008, 283, 28176-28189.	1.6	237
16	Mixtures of Wild-type and a Pathogenic (E22G) Form of $\hat{\pm}^{240}$ in Vitro Accumulate Protofibrils, Including Amyloid Pores. <i>Journal of Molecular Biology</i> , 2003, 332, 795-808.	2.0	229
17	Phosphorylation of Synucleins by Members of the Polo-like Kinase Family. <i>Journal of Biological Chemistry</i> , 2010, 285, 2807-2822.	1.6	204
18	The Impact of the E46K Mutation on the Properties of $\hat{\pm}$ -Synuclein in Its Monomeric and Oligomeric States. <i>Biochemistry</i> , 2007, 46, 7107-7118.	1.2	198

#	ARTICLE	IF	CITATIONS
19	The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α -synuclein, and enhances its secretion and nuclear localization in cells. <i>Human Molecular Genetics</i> , 2014, 23, 4491-4509.	1.4	194
20	Structural Properties of Pore-Forming Oligomers of α -Synuclein. <i>Journal of the American Chemical Society</i> , 2009, 131, 17482-17489.	6.6	191
21	c-Abl phosphorylates α -synuclein and regulates its degradation: implication for α -synuclein clearance and contribution to the pathogenesis of Parkinson's disease. <i>Human Molecular Genetics</i> , 2014, 23, 2858-2879.	1.4	176
22	Resolving molecule-specific information in dynamic lipid membrane processes with multi-resonant infrared metasurfaces. <i>Nature Communications</i> , 2018, 9, 2160.	5.8	176
23	Polo-like kinase 2 regulates selective autophagic α -synuclein clearance and suppresses its toxicity in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E3945-54.	3.3	160
24	Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 3543-3558.	2.5	159
25	α -Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1511-1519.	3.3	156
26	Glycation potentiates α -synuclein-associated neurodegeneration in synucleinopathies. <i>Brain</i> , 2017, 140, 1399-1419.	3.7	153
27	The H50Q Mutation Enhances α -Synuclein Aggregation, Secretion, and Toxicity. <i>Journal of Biological Chemistry</i> , 2014, 289, 21856-21876.	1.6	152
28	Characterization of Semisynthetic and Naturally N ^ε -Acetylated α -Synuclein in Vitro and in Intact Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 28243-28262.	1.6	148
29	The Size of the Proteasomal Substrate Determines Whether Its Degradation Will Be Mediated by Mono- or Polyubiquitylation. <i>Molecular Cell</i> , 2012, 48, 87-97.	4.5	141
30	New Class of Inhibitors of Amyloid- β Fibril Formation. <i>Journal of Biological Chemistry</i> , 2002, 277, 42881-42890.	1.6	133
31	Elucidating the Role of Site-Specific Nitration of α -Synuclein in the Pathogenesis of Parkinson's Disease via Protein Semisynthesis and Mutagenesis. <i>Journal of the American Chemical Society</i> , 2015, 137, 5041-5052.	6.6	131
32	Synthetic polyubiquitinated α -Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17726-17731.	3.3	130
33	α ² Protofibrils Possess a Stable Core Structure Resistant to Hydrogen Exchange. <i>Biochemistry</i> , 2003, 42, 14092-14098.	1.2	127
34	Discovery and characterization of stable and toxic Tau/phospholipid oligomeric complexes. <i>Nature Communications</i> , 2017, 8, 1678.	5.8	117
35	Oxidative and nitrative α -synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. <i>Journal of Neurochemistry</i> , 2013, 125, 491-511.	2.1	116
36	Health hazards of methylammonium lead iodide based perovskites: cytotoxicity studies. <i>Toxicology Research</i> , 2016, 5, 407-419.	0.9	113

#	ARTICLE	IF	CITATIONS
37	Towards Elucidation of the Role of Ubiquitination in the Pathogenesis of Parkinson's Disease with Semisynthetic Ubiquitinated α -Synuclein. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 405-409.	7.2	109
38	Activation of the STING-Dependent Type I Interferon Response Reduces Microglial Reactivity and Neuroinflammation. <i>Neuron</i> , 2017, 96, 1290-1302.e6.	3.8	107
39	Inhibition of α -Synuclein Fibrillization by Dopamine Is Mediated by Interactions with Five C-Terminal Residues and with E83 in the NAC Region. <i>PLoS ONE</i> , 2008, 3, e3394.	1.1	106
40	Reverse engineering Lewy bodies: how far have we come and how far can we go?. <i>Nature Reviews Neuroscience</i> , 2021, 22, 111-131.	4.9	104
41	Extent of N-terminus exposure of monomeric alpha-synuclein determines its aggregation propensity. <i>Nature Communications</i> , 2020, 11, 2820.	5.8	99
42	Phosphorylation of α -Synuclein at Y125 and S129 Alters Its Metal Binding Properties: Implications for Understanding the Role of α -Synuclein in the Pathogenesis of Parkinson's Disease and Related Disorders. <i>ACS Chemical Neuroscience</i> , 2011, 2, 667-675.	1.7	97
43	Identification and nanomechanical characterization of the fundamental single-strand protofilaments of amyloid α -synuclein fibrils. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 7230-7235.	3.3	96
44	Elucidating the Role of C-Terminal Post-Translational Modifications Using Protein Semisynthesis Strategies: α -Synuclein Phosphorylation at Tyrosine 125. <i>Journal of the American Chemical Society</i> , 2012, 134, 5196-5210.	6.6	95
45	Induction of de novo α -synuclein fibrillization in a neuronal model for Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E912-21.	3.3	95
46	How specific are the conformation-specific α -synuclein antibodies? Characterization and validation of 16 α -synuclein conformation-specific antibodies using well-characterized preparations of α -synuclein monomers, fibrils and oligomers with distinct structures and morphology. <i>Neurobiology of Disease</i> , 2020, 146, 105086.	2.1	95
47	Nanoplasmonic mid-infrared biosensor for in vitro protein secondary structure detection. <i>Light: Science and Applications</i> , 2017, 6, e17029-e17029.	7.7	93
48	Monomeric Huntingtin Exon 1 Has Similar Overall Structural Features for Wild-Type and Pathological Polyglutamine Lengths. <i>Journal of the American Chemical Society</i> , 2017, 139, 14456-14469.	6.6	87
49	Mimicking Phosphorylation at Serine 87 Inhibits the Aggregation of Human α -Synuclein and Protects against Its Toxicity in a Rat Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 1536-1544.	1.7	84
50	Protein Semisynthesis Provides Access to Tau Disease-Associated Post-translational Modifications (PTMs) and Paves the Way to Deciphering the Tau PTM Code in Health and Diseased States. <i>Journal of the American Chemical Society</i> , 2018, 140, 6611-6621.	6.6	82
51	Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 65.	2.5	74
52	Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports. <i>Neurobiology of Disease</i> , 2020, 141, 104876.	2.1	71
53	Membrane scission driven by the PROPPIN Atg18. <i>EMBO Journal</i> , 2017, 36, 3274-3291.	3.5	68
54	Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies. <i>Chemical Society Reviews</i> , 2022, 51, 513-565.	18.7	68

#	ARTICLE	IF	CITATIONS
55	Disruption of Amyloid-Derived Peptide Assemblies through the Controlled Induction of a β -Sheet to α -Helix Transformation: Application of the Switch Concept. <i>Angewandte Chemie - International Edition</i> , 2007, 46, 2681-2684.	7.2	67
56	Semisynthetic and <i>in Vitro</i> Phosphorylation of Alpha-Synuclein at Y39 Promotes Functional Partly Helical Membrane-Bound States Resembling Those Induced by PD Mutations. <i>ACS Chemical Biology</i> , 2016, 11, 2428-2437.	1.6	64
57	Phosphorylation of huntingtin at residue T3 is decreased in Huntington's disease and modulates mutant huntingtin protein conformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10809-E10818.	3.3	63
58	N-terminal Huntingtin (Htt) phosphorylation is a molecular switch regulating Htt aggregation, helical conformation, internalization, and nuclear targeting. <i>Journal of Biological Chemistry</i> , 2018, 293, 18540-18558.	1.6	63
59	Photobiomodulation Suppresses Alpha-Synuclein-Induced Toxicity in an AAV-Based Rat Genetic Model of Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0140880.	1.1	62
60	Site-Specific Hyperphosphorylation Inhibits, Rather than Promotes, Tau Fibrillization, Seeding Capacity, and Its Microtubule Binding. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 4059-4067.	7.2	56
61	Mutant Exon1 Huntingtin Aggregation is Regulated by T3 Phosphorylation-Induced Structural Changes and Crosstalk between T3 Phosphorylation and Acetylation at K6. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 5202-5207.	7.2	54
62	A user's guide for α -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017, 32, 1117-1130.	2.2	54
63	Unraveling the complexity of amyloid polymorphism using gold nanoparticles and cryo-EM. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6866-6874.	3.3	54
64	Parkinson Disease Mutant E46K Enhances α -Synuclein Phosphorylation in Mammalian Cell Lines, in Yeast, and in Vivo. <i>Journal of Biological Chemistry</i> , 2015, 290, 9412-9427.	1.6	52
65	Real-Time In Situ Secondary Structure Analysis of Protein Monolayer with Mid-Infrared Plasmonic Nanoantennas. <i>ACS Sensors</i> , 2018, 3, 1109-1117.	4.0	51
66	One-Pot Semisynthesis of Exon 1 of the Huntingtin Protein: New Tools for Elucidating the Role of Posttranslational Modifications in the Pathogenesis of Huntington's Disease. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 1928-1933.	7.2	48
67	Antibody-based methods for the measurement of α -synuclein concentration in human cerebrospinal fluid: method comparison and round robin study. <i>Journal of Neurochemistry</i> , 2019, 149, 126-138.	2.1	44
68	A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α -synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α -synuclein research. <i>Journal of Neurochemistry</i> , 2020, 153, 103-119.	2.1	44
69	Microtubule-Binding R3 Fragment from Tau Self-Assembles into Giant Multistranded Amyloid Ribbons. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 618-622.	7.2	43
70	Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties. <i>Nature Communications</i> , 2021, 12, 6579.	5.8	42
71	One-pot total chemical synthesis of human α -synuclein. <i>Chemical Communications</i> , 2013, 49, 9254.	2.2	40
72	Rethinking protein aggregation and drug discovery in neurodegenerative diseases: Why we need to embrace complexity?. <i>Current Opinion in Chemical Biology</i> , 2021, 64, 67-75.	2.8	40

#	ARTICLE	IF	CITATIONS
73	Switch-peptides as folding precursors in self-assembling peptides and amyloid fibrillogenesis. <i>Biopolymers</i> , 2007, 88, 239-252.	1.2	38
74	Switch Peptide via Staudinger Reaction. <i>Organic Letters</i> , 2008, 10, 5243-5246.	2.4	38
75	Single Posttranslational Modifications in the Central Repeat Domains of Tau4 Impact its Aggregation and Tubulin Binding. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 1616-1620.	7.2	38
76	TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models. <i>EMBO Journal</i> , 2020, 39, e104671.	3.5	34
77	Membrane Permeabilization: A Common Mechanism in Protein-Misfolding Diseases. <i>Science of Aging Knowledge Environment: SAGE KE</i> , 2005, 2005, pe28-pe28.	0.9	33
78	Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models. <i>Scientific Reports</i> , 2017, 7, 5070.	1.6	32
79	Chronic corticosterone aggravates behavioral and neuronal symptomatology in a mouse model of alpha-synuclein pathology. <i>Neurobiology of Aging</i> , 2019, 83, 11-20.	1.5	32
80	Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of Tau. <i>Journal of Biological Chemistry</i> , 2020, 295, 7905-7922.	1.6	32
81	An Intein-based Strategy for the Production of Tag-free Huntingtin Exon 1 Proteins Enables New Insights into the Polyglutamine Dependence of Httex1 Aggregation and Fibril Formation. <i>Journal of Biological Chemistry</i> , 2016, 291, 12074-12086.	1.6	30
82	Parkinson mice show functional and molecular changes in the gut long before motoric disease onset. <i>Molecular Neurodegeneration</i> , 2021, 16, 34.	4.4	29
83	Chemical Strategies for Controlling Protein Folding and Elucidating the Molecular Mechanisms of Amyloid Formation and Toxicity. <i>Journal of Molecular Biology</i> , 2012, 421, 204-236.	2.0	27
84	What about faculty?. <i>ELife</i> , 2020, 9, .	2.8	27
85	Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?. <i>Movement Disorders</i> , 2021, 36, 857-861.	2.2	26
86	Semisynthesis and Enzymatic Preparation of Post-translationally Modified $\hat{\pm}$ -Synuclein. <i>Methods in Molecular Biology</i> , 2016, 1345, 3-20.	0.4	25
87	Exploring the role of post-translational modifications in regulating $\hat{\pm}$ -synuclein interactions by studying the effects of phosphorylation on nanobody binding. <i>Protein Science</i> , 2018, 27, 1262-1274.	3.1	25
88	Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay. <i>Frontiers in Neuroscience</i> , 2019, 13, 889.	1.4	25
89	Enforced dimerization between XBP1s and ATF6f enhances the protective effects of the UPR in models of neurodegeneration. <i>Molecular Therapy</i> , 2021, 29, 1862-1882.	3.7	25
90	Switch-Peptides: Design and Characterization of Controllable Super-Amyloid-Forming Host-Guest Peptides as Tools for Identifying Anti-Amyloid Agents. <i>ChemBioChem</i> , 2008, 9, 2104-2112.	1.3	24

#	ARTICLE	IF	CITATIONS
91	Influence of the β -Sheet Content on the Mechanical Properties of Aggregates during Amyloid Fibrillization. <i>Angewandte Chemie</i> , 2015, 127, 2492-2496.	1.6	22
92	Detection of huntingtin exon 1 phosphorylation by Phos-Tag SDS-PAGE: Predominant phosphorylation on threonine 3 and regulation by IKK β . <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 1317-1322.	1.0	21
93	In Vitro Preparation of Prefibrillar Intermediates of Amyloid- β and β -Synuclein. , 2005, 299, 019-034.		20
94	Amyloid single-cell cytotoxicity assays by nanomotion detection. <i>Cell Death Discovery</i> , 2017, 3, 17053.	2.0	20
95	To target Tau pathologies, we must embrace and reconstruct their complexities. <i>Neurobiology of Disease</i> , 2021, 161, 105536.	2.1	20
96	A NAC domain mutation (E83Q) unlocks the pathogenicity of human alpha-synuclein and recapitulates its pathological diversity. <i>Science Advances</i> , 2022, 8, eabn0044.	4.7	20
97	The Role of Post-translational Modifications on the Energy Landscape of Huntingtin N-Terminus. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 95.	1.6	19
98	Monitoring alpha-synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get. <i>Journal of Neurochemistry</i> , 2021, 157, 872-888.	2.1	18
99	Site-Specific Phosphorylation of Huntingtin Exon-1 Recombinant Proteins Enabled by the Discovery of Novel Kinases. <i>ChemBioChem</i> , 2021, 22, 217-231.	1.3	18
100	Switch-Peptides: From Conformational Studies to Alzheimer's Disease. <i>Chimia</i> , 2006, 60, 199-202.	0.3	17
101	Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates. <i>Scientific Reports</i> , 2021, 11, 17977.	1.6	16
102	The Nt17 Domain and its Helical Conformation Regulate the Aggregation, Cellular Properties and Neurotoxicity of Mutant Huntingtin Exon 1. <i>Journal of Molecular Biology</i> , 2021, 433, 167222.	2.0	15
103	Structural Basis of Huntingtin Fibril Polymorphism Revealed by Cryogenic Electron Microscopy of Exon 1 HTT Fibrils. <i>Journal of the American Chemical Society</i> , 2022, 144, 10723-10735.	6.6	15
104	Molecular Electron Microscopy Approaches to Elucidating the Mechanisms of Protein Fibrillogenesis. , 2005, 299, 081-102.		14
105	Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	14
106	Ultrasensitive quantitative measurement of huntingtin phosphorylation at residue S13. <i>Biochemical and Biophysical Research Communications</i> , 2020, 521, 549-554.	1.0	14
107	Pathological Relevance of Post-Translationally Modified Alpha-Synuclein (pSer87, pSer129, nTyr39) in Idiopathic Parkinson's Disease and Multiple System Atrophy. <i>Cells</i> , 2022, 11, 906.	1.8	14
108	Structural differences of amyloid- β fibrils revealed by antibodies from phage display. <i>BMC Biotechnology</i> , 2015, 15, 57.	1.7	12

#	ARTICLE	IF	CITATIONS
109	Discovery of a Novel Aggregation Domain in the Huntingtin Protein: Implications for the Mechanisms of Htt Aggregation and Toxicity. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 562-567.	7.2	11
110	Single Posttranslational Modifications in the Central Repeat Domains of Tau4 Impact its Aggregation and Tubulin Binding. <i>Angewandte Chemie</i> , 2019, 131, 1630-1634.	1.6	11
111	Site-Specific Hyperphosphorylation Inhibits, Rather than Promotes, Tau Fibrillization, Seeding Capacity, and Its Microtubule Binding. <i>Angewandte Chemie</i> , 2020, 132, 4088-4096.	1.6	11
112	Fatal attraction – The role of hypoxia when alpha-synuclein gets intimate with mitochondria. <i>Neurobiology of Aging</i> , 2021, 107, 128-141.	1.5	11
113	A New Caged-Glutamine Derivative as a Tool To Control the Assembly of Glutamine-Containing Amyloidogenic Peptides. <i>ChemBioChem</i> , 2016, 17, 2353-2360.	1.3	8
114	A New Chemoenzymatic Semisynthetic Approach Provides Insight into the Role of Phosphorylation beyond Exon1 of Huntingtin and Reveals N-Terminal Fragment Length-Dependent Distinct Mechanisms of Aggregation. <i>Journal of the American Chemical Society</i> , 2021, 143, 9798-9812.	6.6	8
115	Investigating Crosstalk Among PTMs Provides Novel Insight Into the Structural Basis Underlying the Differential Effects of Nt17 PTMs on Mutant Httex1 Aggregation. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 686086.	1.6	8
116	Pronounced β -Synuclein Pathology in a Seeding-Based Mouse Model Is Not Sufficient to Induce Mitochondrial Respiration Deficits in the Striatum and Amygdala. <i>ENeuro</i> , 2020, 7, ENEURO.01110-20.2020.	0.9	8
117	Correlative light and electron microscopy suggests that mutant huntingtin dysregulates the endolysosomal pathway in presymptomatic Huntington's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 70.	2.4	7
118	Frontispiece: Mutant Exon1 Huntingtin Aggregation is Regulated by T3 Phosphorylation-Induced Structural Changes and Crosstalk between T3 Phosphorylation and Acetylation at K6. <i>Angewandte Chemie - International Edition</i> , 2017, 56, .	7.2	6
119	Amyloids Go Genomic: Insights Regarding the Sequence Determinants of Prion Formation from Genome-Wide Studies. <i>ChemBioChem</i> , 2009, 10, 1951-1954.	1.3	5
120	Alpha-Synuclein oligomerization and aggregation: All models are useful but only if we know what they model. <i>Journal of Neurochemistry</i> , 2021, 157, 891-898.	2.1	5
121	Lewy body-associated proteins: victims, instigators, or innocent bystanders? The case of AIMP2 and alpha-synuclein. <i>Neurobiology of Disease</i> , 2021, 156, 105417.	2.1	4
122	Non-monotonic fibril surface occlusion by GFP tags from coarse-grained molecular simulations. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 309-321.	1.9	4
123	Mutant Exon1 Huntingtin Aggregation is Regulated by T3 Phosphorylation-Induced Structural Changes and Crosstalk between T3 Phosphorylation and Acetylation at K6. <i>Angewandte Chemie</i> , 2017, 129, 5286-5291.	1.6	2
124	Frontispiz: Mutant Exon1 Huntingtin Aggregation is Regulated by T3 Phosphorylation-Induced Structural Changes and Crosstalk between T3 Phosphorylation and Acetylation at K6. <i>Angewandte Chemie</i> , 2017, 129, .	1.6	1
125	Education and research are essential for lasting peace in Yemen. <i>Lancet, The</i> , 2020, 395, 1114.	6.3	1
126	Remembering John Q Trojanowski, in his own words: A life dedicated to discovering building blocks and using them to build bridges of knowledge, collaboration, and discovery. <i>Npj Parkinson's Disease</i> , 2022, 8, 43.	2.5	1

#	ARTICLE	IF	CITATIONS
127	On-Demand Nanoliter Sampling Probe for the Collection of Brain Fluid. Analytical Chemistry, 2022, 94, 10415-10426.	3.2	1
128	02â€09â€04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF Î±â€SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH. Alzheimer's and Dementia, 2018, 14, P642.	0.4	0